Table 10. Statin Effects on Aggression in Women.

	Statin				Simvastatin				Pravastatin
	N	Beta (SE)	95% CI	P vs placebo	N	Beta (SE)	95% CI	P vs placebo	N	Beta (SE)	95% CI	P vs placebo
ΔOASMa, all women	311	0.59 (0.35)	-0.11, 1.3	0.098	207	0.87 (0.51)	-0.14, 1.9	0.092	208	0.29 (0.38)	-0.46, 1.0	0.45
ΔOASMa Excluding one participant 412	310	0.70 (0.34)	0.035, 1.4	0.039	206	0.98 (0.50)	-0.010, 2.0	0.052	207	0.40 (0.36)	-0.32, 1.1	0.27
ΔOASMa all Age ≥45	304	0.68 (0.34)	0.0053, 1.4	0.048	202	0.95 (0.51)	-0.054, 2.0	0.063	203	0.39 (0.37)	-0.34, 1.1	0.30
ΔOASMa all Age ≥ 50	288	0.71 (0.35)	0.018, 1.4	0.044	194	1.1 (0.54)	0.017, 2.2	0.046	194	0.33 (0.37)	-0.40, 1.0	0.37
ΔOASMa all Age ≥ 55	238	0.77 (0.39)	0.0040, 1.5	0.049	158	1.3 (0.61)	0.11, 2.5	0.033	160	0.24 (0.38)	-0.50, 0.98	0.52

Beta = regression coefficient; CI = confidence interval; OASMa = Overt-Aggression-Scale-Modified–Aggression-Subscale; SE = standard error. A statin x age interaction term, e.g. binarizing at age 55 (years) was significant for simvastatin (P = 0.039), and borderline significant for combined statins (P = 0.092). Women age <45 years, including participant 412: Statin: n = 7; β = -0.79 (SE = 2.5) 95%CI = -7.9, 6.3; P = 0.77. Simvastatin: n = 5; β = 0.15 (SE = 4.8) 95%CI = -20.5, 20.8; P = 0.98. Pravastatin: n = 5; β = -1.2 (SE = 3.3) 95%CI = -15.3, 12.9; P = 0.74. Women age <45 years, excluding participant 412: Statin: n = 6; β = 3.5 (SE = 1.8) 95%CI = -2.2, 9.2; P = 0.15. Simvastatin: n = 4; β = 5.0 (SE = 1.4) 95%CI = -13.0, 23.0; P = 0.18. Pravastatin: n = 4; β = 2.0 (SE = 1.4) 95%CI = -16.0, 20.0; P = 0.39.